A Phase 4 interventional study of Henagliflozin 5mg and Henagliflozin 10mg in PreDiabetes, Prediabetic State and Type 2 Diabetes, sponsored by Shandong Provincial Hospital. Not yet recruiting at 50 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-07.
Sponsored by Shandong Provincial Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.
Among the 51 studies in Prediabetic State with a site in China, this one is the 9th largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 in phase 4, reaches primary completion later than 8 of the 24 other live ones, and was the 32nd registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Argentina and 9 more countries
Ages 18+
Yang Zhang · Sites in China
Ages 60–79
Zhujiang Hospital · Sites in China
Ages 18–60
Beijing Anzhen Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3 · Phase 4 8
First in 2008; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 984 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 160 across the 44 interventional studies, 2,800 across the 7 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 51 have an industry lead sponsor. The 10 most frequent:
Shandong Provincial Hospital is the lead sponsor of 64 studies on the registry; 26 are open to participants now.
Shandong Provincial Hospital has 3 studies filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
12 of the studies in Prediabetic State with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448130Shandong Provincial HospitalHenagliflozin's Impact on Prediabetes Remission | 2026-12 |
| NCT07289880The First Affiliated Hospital of Guangdong Pharmaceutical UniversityEfficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes | 2026-12-01 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
| NCT07271745Chunyan MaMulticenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 51 studies in Prediabetic State with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates the effectiveness of Henagliflozin combined with lifestyle interventions for managing patients with prediabetes. As global prediabetes rates rise, increasing the risk of diabetes and vascular issues, addressing treatment gaps is essential. Henagliflozin, a novel SGLT2 inhibitor developed in China, aims to improve glucose control and metabolic health when paired with lifestyle changes.
The study's primary objectives include: assessing whether Henagliflozin can achieve normoglycemia in prediabetic patients after 6 months of treatment.
The trial will compare three groups (Henagliflozin 5mg, 10mg, and a placebo), focusing on efficacy and safety. Participants, assigned randomly, will undergo a 6-month treatment phase and an 18-month follow-up. Regular health assessments will monitor glucose levels, metabolic health, and risks of major complications like cardiovascular events and microvascular diseases, with additional evaluations of C-peptide and insulin changes.
Structured as a multicenter, randomized, double-blind, placebo-controlled study, it involves 984 prediabetic adults across 50 medical institutions in China. This comprehensive approach could redefine prediabetes management by integrating drug therapy with lifestyle modifications.
This research is launched in light of the global surge in prediabetes, a condition that markedly increases the risk of developing type 2 diabetes and related vascular complications. While lifestyle modifications are the frontline defense against prediabetes, the variability in individual responses often requires the integration of pharmacological treatments. Studies have shown that drugs such as metformin, acarbose, SGLT2 inhibitors, GLP-1 agonists, GIP/GLP-1 receptor agonists, thiazolidinediones, and orlistat effectively curb the progression to diabetes. Yet, there remains a gap in specific research addressing the intervention needs of the prediabetic population in China.
Currently, acarbose is the only drug approved in the Chinese market for treating patients with impaired glucose tolerance, highlighting a limited range of therapeutic options for prediabetes. SGLT2 inhibitors, as a newer class of hypoglycemic agents, have demonstrated significant promise in reducing major cardiovascular events in high-risk patients with type 2 diabetes, enhancing outcomes in heart failure, and providing renal protection. However, there is a scarcity of large-scale, prospective studies on the impact of SGLT2 inhibitors in prediabetes. Henagliflozin, the first original SGLT2 inhibitor developed in China and launched on December 31, 2021, is being studied to assess its effectiveness combined with lifestyle interventions in the prediabetic demographic, aiming to fill a crucial void in the current treatment paradigm.
This study aims to assess the combined benefits of Henagliflozin and lifestyle modifications in managing prediabetes. The investigators conducted a two-year prospective, randomized, double-blind, placebo-controlled trial across 50 medical institutions in various provinces of China. It is planned to enroll 984 adult prediabetic patients who had not previously been treated with antidiabetic medications. Participants meeting inclusion criteria were randomly assigned to one of three groups: Henagliflozin 5mg, Henagliflozin 10mg, or placebo. The intensive intervention phase, consisting of pharmacotherapy combined with lifestyle changes, lasted for 6 months, followed by an 18-month follow-up period focusing solely on lifestyle interventions.
The primary endpoint is the proportion of participants achieving normoglycemia after 6 months of intervention, with subsequent assessments at 12 months. Secondary endpoints include short-term (0-12 months) and long-term (12-24 months) changes in glucose control, metabolic indicators such as body weight, body mass index (BMI), body fat content, waist and hip circumference, lipid profiles, blood pressure, serum uric acid levels, hepatic steatosis, and carotid intima-media thickness. Exploratory outcomes encompass changes in C-peptide and insulin levels from baseline to 6 months, and the risk of major adverse cardiovascular events (MACE) from baseline to 24 months and beyond.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Henagliflozin 5mg+ placebo 10mg po qd + lifestyle intervention for 6 months
Drug: Henagliflozin 5mg
Henagliflozin 10mg+ placebo 5mg po qd + lifestyle intervention for 6 months
Drug: Henagliflozin 10mg
placebo 10mg + placebo 5mg po qd + lifestyle intervention for 6 months
Drug: Placebo
Henagliflozin 5mg + lifestyle intervention
Also known as: lifestyle intervention
Henagliflozin 10mg+ lifestyle intervention
Also known as: lifestyle intervention
Placebo+ lifestyle intervention
Also known as: lifestyle intervention
Normoglycemia Achievement Rates Post-6-Month Intervention
This measure assesses the proportion of participants who achieve normoglycemia from the end of a 6-month intervention until the 12-month assessment point. Normoglycemia is defined as fasting plasma glucose (FPG) less than 6.1 mmol/L and 2-hour post-prandial glucose (2h-PPG) less than 7.8 mmol/L. The measure includes rates of sustained remission (normal glycemic status lasting more than 6 months post-medication cessation), partial remission (lasting 3-6 months), and temporary remission (lasting less than 3 months).
Time frame: From 6 months post-intervention to 12 months
Blood Glucose Control Normalization
Proportion and duration of normalization of blood glucose levels within 24 months in the three study groups.
Time frame: From 6 months post-intervention to 24 months
Incidence of New-Onset Type 2 Diabetes
Incidence of new-onset type 2 diabetes within 24 months in the three study groups.
Time frame: From 0 to 24 months
Changes in HbA1c Levels
Changes in HbA1c levels over the 24-month period in the three study groups.
Time frame: From 0 to 24 months
Impact of Glycemic Status at 12 Months
Impact of glycemic status at 12 months on subsequent reversal to normoglycemia and risk of new-onset type 2 diabetes during the 12-24 month follow-up period in the three study groups.
Time frame: From 12 months to 24 months
Changes in blood pressure over 24 Months
Changes in systolic and diastolic blood pressure in the three study groups over 24 Months.
Time frame: From 0 to 24 months
Changes in serum uric acid levels over 24 Months
Changes in serum uric acid levels in the three study groups over 24 Months.
Time frame: From 0 to 24 months
Changes in hepatic steatosis over 24 Months
Changes in hepatic steatosis assessed by abdominal ultrasound in the three study groups over 24 Months.
Time frame: From 0 to 24 months
Changes in carotid intima-media thickness over 24 Months
Changes in carotid intima-media thickness measured by carotid ultrasound in the three study groups over 24 Months.
Time frame: From 0 to 24 months
Changes in Total Cholesterol (TC) over 24 Months
Measurement of Total Cholesterol (TC) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.
Time frame: From 0 to 24 months
Changes in Triglycerides (TG) over 24 Months
Measurement of Triglycerides (TG) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.
Time frame: From 0 to 24 months
Changes in Low-Density Lipoprotein Cholesterol (LDL-c) over 24 Month
Measurement of Low-Density Lipoprotein Cholesterol (LDL-c) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.
Time frame: From 0 to 24 months
Changes in High-Density Lipoprotein Cholesterol (HDL-c) over 24 Months
Measurement of High-Density Lipoprotein Cholesterol (HDL-c) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.
Time frame: From 0 to 24 months
Changes in Body Weight over 24 Months
Measurement of body weight in kilograms (kg) at multiple time points within the 24-month period.
Time frame: From 0 to 24 months
Changes in Body Mass Index (BMI) over 24 Months
Calculation of BMI in kg/m² using the formula: weight (kg) / (height (m)²), measured at multiple time points within the 24-month period.
Time frame: From 0 to 24 months
Changes in Body Fat Content over 24 Months
Measurement of body fat content as a percentage (%) of total body weight at multiple time points within the 24-month period.
Time frame: From 0 to 24 months
Changes in Waist Circumference over 24 Months
Measurement of waist circumference in centimeters (cm) at multiple time points within the 24-month period.
Time frame: From 0 to 24 months
Changes in Hip Circumference over 24 Months
Measurement of hip circumference in centimeters (cm) at multiple time points within the 24-month period.
Time frame: From 0 to 24 months
Changes in C-peptide Levels over the First 6 Months
Measurement of C-peptide levels in nanomoles per liter (nmol/L) at multiple time points within the 6-month period.
Time frame: From 0 to 6 months
Changes in Insulin Levels over the First 6 Months
Measurement of insulin levels in milliunits per liter (mU/L) at multiple time points within the 6-month period.
Time frame: From 0 to 6 months
Major Adverse Cardiovascular Events
Major Adverse Cardiovascular Events (MACE) in the three study groups over 0-24 months.
Time frame: From 0 to 24 months
Risk of Retinal Diseases
Risk of retinal diseases (e.g., diabetic retinopathy) in the three study groups over 0-24 months.
Time frame: From 0 to 24 months
Risk of Renal diseases
Risk of renal diseases (e.g., diabetic nephropathy/chronic kidney disease) in the three study groups over 0-24 months.
Time frame: From 0 to 24 months
Plan to share: Undecided — We have opted for 'Undecided' regarding the sharing of individual participant data (IPD) at this stage. Our decision is pending as we are currently engaged in ongoing discussions and evaluations regarding the most appropriate approach to IPD sharing for our research. Factors such as ethical considerations, data sensitivity, and regulatory requirements are being carefully assessed. We aim to reach a well-informed decision in due course and will update our IPD sharing plan accordingly. Thank you for your understanding as we navigate through this process.
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Dec 2026, 30 months later.
Of 30 phase 4 interventional studies under Prediabetic State, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 47. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Henagliflozin
Shandong Provincial Hospital